<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238650</url>
  </required_header>
  <id_info>
    <org_study_id>MB02 A 04-18</org_study_id>
    <nct_id>NCT04238650</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Double Blind, Two-Arm, Single Dose, Parallel Phase I Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (a Proposed Bevacizumab Biosimilar Drug) and EU Approved Avastin® in Japanese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mAbxience S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>mAbxience S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomised, Double Blind, Two-Arm, Single Dose, Parallel Phase I Study To Compare the&#xD;
      Pharmacokinetics, Safety and Immunogenicity of MB02 (a Proposed Bevacizumab Biosimilar Drug)&#xD;
      and EU Approved Avastin® in Japanese Healthy Male Volunteers.&#xD;
&#xD;
      During the course of the study, the similarity in pharmacokinetics will be assessed by&#xD;
      sampling the levels of drug in the blood, and by comparing these levels among the different&#xD;
      administration arms. Safety, tolerability, and immunologic response to the administered drugs&#xD;
      will also be evaluated throughout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary PK parameter endpoint is AUC(0-∞) for bevacizumab. The secondary PK endpoints&#xD;
      will include all other PK parameters for bevacizumab, including Cmax, tmax, t1/2, CL and&#xD;
      AUClast.&#xD;
&#xD;
      The serum PK parameters of bevacizumab will be calculated using standard noncompartmental&#xD;
      methods. An analysis of covariance model will be used to analyse the log-transformed primary&#xD;
      PK parameters (AUC[0-∞] and Cmax) and AUClast. The model will include a fixed effect for&#xD;
      treatment and body weight as a covariate.&#xD;
&#xD;
      All other PK parameters will not be subject to inferential statistical analysis.&#xD;
&#xD;
      Estimates of geometric mean ratios together with the corresponding 90% confidence intervals&#xD;
      (CI) will be derived for the comparisons of the PK parameters as follows:&#xD;
&#xD;
      • MB02 versus EU Avastin®&#xD;
&#xD;
      A mixed effects model with treatment arm as fixed effect will be used to compare&#xD;
      natural-logarithmic transformed PK parameters (AUC[0-∞+, AUClast and Cmax) between the two&#xD;
      treatment arms (MB02 vs EU-approved Avastin®)&#xD;
&#xD;
      PK similarity between arms will be concluded if the 90% confidence intervals (CIs) for the&#xD;
      geometric mean test/reference ratio of AUC(0-∞) fell within the predefined 0.80-1.25&#xD;
      bioequivalence interval.&#xD;
&#xD;
      All AEs will be listed and summarised using descriptive methodology. All observed or&#xD;
      patient-reported AEs will be graded by the National Cancer Institute Common Terminology&#xD;
      Criteria for Adverse Events version 5.0. The incidence of AEs for each treatment will be&#xD;
      presented by severity and by association with the study drugs as determined by the&#xD;
      Investigator (or designee). Each AE will be coded using the Medical Dictionary for Regulatory&#xD;
      Activities. All safety data will be listed and summarised as appropriate.&#xD;
&#xD;
      Immunogenicity data (overall ADA incidence and titers, and neutralising ADA results) will be&#xD;
      listed. A summary of the number and percent of subjects testing positive for ADA or&#xD;
      neutralising antibodies before the dose of MB02, EU Avastin® (Day -1) and at scheduled&#xD;
      post-dose assessments will be presented by treatment arm. All safety data and immunogenicity&#xD;
      data summaries will be based on the safety analysis population. Select analyses may be&#xD;
      repeated for subsets with or without ADA and de novo ADA formation as appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Actual">December 27, 2019</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]</measure>
    <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
    <description>To compare the pharmacokinetic (PK) profiles of MB02 and EU Avastin® (in terms of AUC(0-∞)]) in Japanese population to establish bioequivalence between the 2 study drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
    <description>To evaluate and compare the Cmax of MB02 and EU Avastin® in Japanese population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration (AUClast)</measure>
    <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
    <description>To evaluate and compare the AUClast of MB02 and EU Avastin® in Japanese population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Serum Concentration (Tmax)</measure>
    <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
    <description>To evaluate and compare the tmax of MB02 and EU Avastin® in Japanese population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Serum Terminal Elimination Half Life (t1/2)</measure>
    <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
    <description>To evaluate and compare the t1/2 of MB02 and EU Avastin® in Japanese population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CL)</measure>
    <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
    <description>To evaluate and compare the CL of MB02 and EU Avastin® in Japanese population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vz)</measure>
    <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
    <description>To evaluate and compare the Vz of MB02 and EU Avastin® in Japanese population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-related Adverse Events (Safety)</measure>
    <time_frame>Day 1 - Day 70</time_frame>
    <description>Compare the incidence of TEAEs reported in each treatment arm using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADA Including Nab (Immunogenicity)</measure>
    <time_frame>Day -1, Day 14, 28, 50 and 70.</time_frame>
    <description>Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Male</condition>
  <condition>Japanese</condition>
  <arm_group>
    <arm_group_label>MB02 (Bevacizumab Biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU approved Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB02 (Bevacizumab Biosimilar)</intervention_name>
    <description>Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
    <arm_group_label>MB02 (Bevacizumab Biosimilar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU approved Avastin®</intervention_name>
    <description>Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
    <arm_group_label>EU approved Avastin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by&#xD;
             the study restrictions. Subjects must have signed an informed consent before any&#xD;
             study-related procedure or evaluation is performed.&#xD;
&#xD;
          2. Healthy Japanese males aged ≥20 to ≤55 years, inclusive, at Screening.&#xD;
&#xD;
          3. Subjects with Body mass index (BMI) between ≥18.5 to ≤28 kg/m2 and total body weight&#xD;
             between ≥50 and ≤100 kg, at Screening&#xD;
&#xD;
          4. Subject must have no clinically relevant abnormalities identified by a detailed&#xD;
             medical history.&#xD;
&#xD;
          5. Systolic blood pressure ≤140 mm Hg and diastolic blood pressure ≤90 mm Hg.&#xD;
&#xD;
          6. Computerized (12-lead) electrocardiogram (ECG) recording without signs of clinically&#xD;
             relevant pathology.&#xD;
&#xD;
          7. All other values for hematology, coagulation and for biochemistry and urinalysis tests&#xD;
             of blood and urine within the normal range or showing no clinically relevant&#xD;
             deviations as judged by the Investigator, according to the following laboratory&#xD;
             values:&#xD;
&#xD;
             Adequate bone marrow function&#xD;
&#xD;
               -  Absolute neutrophil count ≥1.5 × 109 L&#xD;
&#xD;
               -  Platelet count ≥100 × 109 L&#xD;
&#xD;
               -  Hemoglobin &gt;10 g/dl&#xD;
&#xD;
             Adequate liver function:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ ULN&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≤1.5 × ULN&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 × ULN&#xD;
&#xD;
               -  Serum albumin: &gt;3.5 g/dL&#xD;
&#xD;
               -  Low density lipoprotein cholesterol ≤139 mg/dL&#xD;
&#xD;
               -  High density lipoprotein cholesterol ≥ 40 mg/dL&#xD;
&#xD;
               -  Creatine kinase (CK) &lt;2 ULN at D-1&#xD;
&#xD;
             Adequate coagulation:&#xD;
&#xD;
             • International normalised ratio (INR) 0.8 to 1.3&#xD;
&#xD;
             Adequate renal function:&#xD;
&#xD;
               -  Blood urea nitrogen: ≤1.5 × ULN&#xD;
&#xD;
               -  Creatinine: &lt;1.5 mg/dL&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt;2+.&#xD;
&#xD;
          8. All intermittent medications should have been stopped at least 30 days prior to&#xD;
             admission to the clinical research center.&#xD;
&#xD;
          9. Subjects agree to use contraception.&#xD;
&#xD;
         10. Ability and willingness to abstain from alcoholic beverages (alcohol) 48 hours prior&#xD;
             to admission to the clinical research center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of relevant allergy/hypersensitivity (including allergy to drug or its&#xD;
             excipients).&#xD;
&#xD;
          2. Previous treatment with an anti VEGF antibody like bevacizumab or any other protein or&#xD;
             antibody targeting the VEGF receptor.&#xD;
&#xD;
          3. History of bleeding disorders or protein C, protein S, and/or factor V Leiden&#xD;
             deficiency.&#xD;
&#xD;
          4. Known history of clinically significant essential hypertension (subjects under any&#xD;
             antihypertensive treatment included), orthostatic hypotension, fainting spells or&#xD;
             blackouts for any reason, cardiac failure or history of thromboembolic conditions.&#xD;
&#xD;
          5. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel&#xD;
             disease, diverticular disease, diverticular disease, any fistulae, pulmonary&#xD;
             hemorrhage (hemoptysis) or reversible posterior leukoencephalopathy syndrome.&#xD;
&#xD;
          6. Any out-of-range laboratory values considered clinically significant by the&#xD;
             investigator.&#xD;
&#xD;
          7. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee).&#xD;
&#xD;
          8. Any current or recent history of active infections, including localized infections.&#xD;
             (Within 2 months prior Screening Visit for any serious infection which requires&#xD;
             hospitalization or intravenous anti-infective, and within 14 days prior Screening&#xD;
             Visit for any active infection which requires oral treatment). A negative result for&#xD;
             human immunodeficiency virus (HIV), Hepatitis B (Hep B), and hepatitis C (Hep C) is&#xD;
             required for participation. If subject shows positive Hepatitis B test, but results&#xD;
             are compatible with prior immunisation and not infection may be included at the&#xD;
             discretion of the Investigator.&#xD;
&#xD;
          9. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to&#xD;
             Check-in, and/or positive urinary drug test screen and/or positive breath alcohol test&#xD;
             at Screening or Check in. Average intake of more than 24 units of alcohol / wk. (1&#xD;
             unit of alcohol equals ~250mL of beer, 100mL of wine or 35mL of spirits). Positive&#xD;
             urine drug screen (opiates, methadone, cocaine, amphetamines (including ecstasy or&#xD;
             methamphetamines), cannabinoids, barbiturates, benzodiazepines, tricyclic&#xD;
             antidepressants and phencyclidine).&#xD;
&#xD;
         10. Treatment with non-topical medications within 7 days prior to study drug&#xD;
             administration, with the exception of hormonal contraceptives, multivitamins, vitamin&#xD;
             C, food supplements and a limited amount of acetaminophen, which may be used&#xD;
             throughout the study.&#xD;
&#xD;
         11. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 60 days prior to Check-in, or within 5 half lives of&#xD;
             the investigational drug used in the study.&#xD;
&#xD;
         12. Subjects considered unsuitable for inclusion by the investigator (e.g., inability to&#xD;
             understand and comply with the study requirements or presence of any condition which,&#xD;
             in the opinion of the investigator, would not allow safe participation in the study).&#xD;
&#xD;
         13. Strenuous exercise within seven days prior to admission to the clinical research&#xD;
             center.&#xD;
&#xD;
         14. Significant or acute illness within 15 days prior to drug administration that may&#xD;
             impact safety assessments per the judgement of the investigator.&#xD;
&#xD;
         15. Unsuitable veins for infusion and/or venepuncture.&#xD;
&#xD;
         16. History of, or planned surgery, including suturing, dental surgery or wound dehiscence&#xD;
             within 30 days of dosing, or within 30 days of the last study visit. Presence of a&#xD;
             nonhealing wound or fracture.&#xD;
&#xD;
         17. Medically significant dental disease or dental neglect with signs and or symptoms of&#xD;
             local or systemic infection that would likely require a dental procedure during the&#xD;
             course of the study.&#xD;
&#xD;
         18. Use or intend to use slow-release medications/products considered to still be active&#xD;
             within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
         19. Have received a live or attenuated vaccine from 3 months prior to Screening or have&#xD;
             the intention to receive a vaccine during the study.&#xD;
&#xD;
         20. Intend to travel to a region where a vaccination will be required due to endemic&#xD;
             disease within 3 months of dosing.&#xD;
&#xD;
         21. Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or&#xD;
             positive cotinine test upon Screening or Check-in.&#xD;
&#xD;
         22. Receipt of blood products within 60 days prior to Check-in.&#xD;
&#xD;
         23. Person who performed blood sampling more than 400 mL within 90 days before&#xD;
             administration of investigational drug, more than 200 mL blood within 30 days, or&#xD;
             blood donation of blood plasma / platelet component within 14 days.&#xD;
&#xD;
         24. History of abnormal peripheral sensation including paraesthesia and/or numbness in&#xD;
             arms and/or legs.&#xD;
&#xD;
         25. Have previously received Bevacizumab either under present study or under any other&#xD;
             circumstances.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only Japanese male subjects may be enrolled</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takashi ETO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SOUSEIKAI Hakata Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SOUSEIKAI Hakata Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <results_first_submitted>December 9, 2020</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT04238650/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT04238650/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 49 subjects were randomized and assigned to one of the study groups (24 to the MB02 arm and 25 to the EU Avastin arm). One subject that was randomized to EU Avastin® withdrew before receiving any study drug dose. Therefore, 48 subjects started the study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MB02 (Bevacizumab Biosimilar)</title>
          <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
        </group>
        <group group_id="P2">
          <title>EU Approved Avastin®</title>
          <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25">One subject was enrolled and randomized to EU Avastin® but the subject was not dosed (subject withdrawal before study drug administration)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MB02 (Bevacizumab Biosimilar)</title>
          <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
        </group>
        <group group_id="B2">
          <title>EU Approved Avastin®</title>
          <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="5.9"/>
                    <measurement group_id="B2" value="28.5" spread="6.6"/>
                    <measurement group_id="B3" value="28.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="9.48"/>
                    <measurement group_id="B2" value="68.5" spread="9.13"/>
                    <measurement group_id="B3" value="67.75" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.54" spread="2.26"/>
                    <measurement group_id="B2" value="23.33" spread="2.84"/>
                    <measurement group_id="B3" value="22.94" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]</title>
        <description>To compare the pharmacokinetic (PK) profiles of MB02 and EU Avastin® (in terms of AUC(0-∞)]) in Japanese population to establish bioequivalence between the 2 study drugs.</description>
        <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
        <population>Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)]</title>
          <description>To compare the pharmacokinetic (PK) profiles of MB02 and EU Avastin® (in terms of AUC(0-∞)]) in Japanese population to establish bioequivalence between the 2 study drugs.</description>
          <population>Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.</population>
          <units>ng*h/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30200000" spread="14.7"/>
                    <measurement group_id="O2" value="29000000" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 0.80-1.25. The PK parameter AUC[0-∞] was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of GLSM</param_type>
            <param_value>1.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.981</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax)</title>
        <description>To evaluate and compare the Cmax of MB02 and EU Avastin® in Japanese population.</description>
        <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
        <population>Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax)</title>
          <description>To evaluate and compare the Cmax of MB02 and EU Avastin® in Japanese population.</description>
          <population>Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.</population>
          <units>ng/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92900" spread="22.1"/>
                    <measurement group_id="O2" value="82300" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (Cmax) falls completely within the range 0.80-1.25. The PK parameter Cmax was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of GLSM</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration (AUClast)</title>
        <description>To evaluate and compare the AUClast of MB02 and EU Avastin® in Japanese population.</description>
        <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
        <population>Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration (AUClast)</title>
          <description>To evaluate and compare the AUClast of MB02 and EU Avastin® in Japanese population.</description>
          <population>Overall number of participants analyzed equals to number of subjects who contributed to summary statistics.</population>
          <units>ng*h/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28200000" spread="12.3"/>
                    <measurement group_id="O2" value="26800000" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 0.80-1.25. The PK parameter AUClast was log-transformed (base e) prior to analysis and was analysed using an ANCOVA model. The model included treatment as a fixed effect and body weight as a covariate.</non_inferiority_desc>
            <param_type>Ratio of GLSM</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.997</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Serum Concentration (Tmax)</title>
        <description>To evaluate and compare the tmax of MB02 and EU Avastin® in Japanese population.</description>
        <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Serum Concentration (Tmax)</title>
          <description>To evaluate and compare the tmax of MB02 and EU Avastin® in Japanese population.</description>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="1.52" upper_limit="24.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.52" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Serum Terminal Elimination Half Life (t1/2)</title>
        <description>To evaluate and compare the t1/2 of MB02 and EU Avastin® in Japanese population.</description>
        <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Serum Terminal Elimination Half Life (t1/2)</title>
          <description>To evaluate and compare the t1/2 of MB02 and EU Avastin® in Japanese population.</description>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430" spread="16.4"/>
                    <measurement group_id="O2" value="450" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Clearance (CL)</title>
        <description>To evaluate and compare the CL of MB02 and EU Avastin® in Japanese population.</description>
        <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CL)</title>
          <description>To evaluate and compare the CL of MB02 and EU Avastin® in Japanese population.</description>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00660" spread="18.3"/>
                    <measurement group_id="O2" value="0.00702" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vz)</title>
        <description>To evaluate and compare the Vz of MB02 and EU Avastin® in Japanese population.</description>
        <time_frame>Predose, end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 38, Day 50, Day 62, and Day 70.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz)</title>
          <description>To evaluate and compare the Vz of MB02 and EU Avastin® in Japanese population.</description>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="13.2"/>
                    <measurement group_id="O2" value="4.56" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment-related Adverse Events (Safety)</title>
        <description>Compare the incidence of TEAEs reported in each treatment arm using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.</description>
        <time_frame>Day 1 - Day 70</time_frame>
        <population>TEAEs were assessed in the Safety population. Subjects receiving MB02 or EU Avastin® and with at least 1 post-dose safety assessment comprised the Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-related Adverse Events (Safety)</title>
          <description>Compare the incidence of TEAEs reported in each treatment arm using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.</description>
          <population>TEAEs were assessed in the Safety population. Subjects receiving MB02 or EU Avastin® and with at least 1 post-dose safety assessment comprised the Safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs of mild severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs of moderate severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs of severe severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects discontinued due to TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of ADA Including Nab (Immunogenicity)</title>
        <description>Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.</description>
        <time_frame>Day -1, Day 14, 28, 50 and 70.</time_frame>
        <population>Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>MB02 (Bevacizumab Biosimilar)</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
          <group group_id="O2">
            <title>EU Approved Avastin®</title>
            <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of ADA Including Nab (Immunogenicity)</title>
          <description>Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.</description>
          <population>Safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1-Day 70</time_frame>
      <desc>Coded according to Medical Dictionary for Regulatory Activities (version 22.1), and graded on the basis of the US National Cancer Institute's Common Terminology for Adverse Events (version 5.0).&#xD;
For the purpose of safety reporting in healthy volunteers, all serious adverse events were considered unexpected and reported as suspected unexpected adverse reactions (SUSARs).</desc>
      <group_list>
        <group group_id="E1">
          <title>MB02 (Bevacizumab Biosimilar)</title>
          <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
        </group>
        <group group_id="E2">
          <title>EU Approved Avastin®</title>
          <description>Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.&#xD;
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susana Millan</name_or_title>
      <organization>mAbxience</organization>
      <phone>+34917711500</phone>
      <email>susana.millan@mabxience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

